OrbiMed Advisors LLC Increases Stake in Forte Biosciences, Inc. to 4.3%

On May 15, 2026, OrbiMed Advisors LLC and OrbiMed Capital LLC filed a joint Amendment No. 1 to Schedule 13G regarding their holdings in Forte Biosciences, Inc. (FBRX). The filing indicates that OrbiMed Advisors LLC now beneficially owns 884,230 shares of Common Stock, representing a 4.3% ownership stake. Additionally, OrbiMed Capital LLC reported beneficial ownership of 312,725 shares, or 1.5% of the company. In the aggregate, the reporting persons hold 5.8% of the issuer's common stock on behalf of other persons. The securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control of the issuer. The investment and voting power are exercised through a management committee consisting of Carl L. Gordon, Sven H. Borho, and W. Carter Neild. This amendment reflects an increase from a previously reported 0.0% position for OrbiMed Advisors LLC as of the event date of March 31, 2026.